TH

Theralink Technologies IncOOTC THER Stock Report

Last reporting period 31 Dec, 2023

Updated 12 Nov, 2024

Last price

Market cap $B

7.5

Middle

Exchange

OOTC - OTC

THER Stock Analysis

TH

Uncovered

Theralink Technologies Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-51/100

Low score

Market cap $B

7.5

Dividend yield

Shares outstanding

6 151.5 B

Theralink Technologies, Inc. is a commercial-stage precision medicine and molecular data-generating company. The Company focuses on the development and commercialization of a series of data-generating assays that provide actionable information for physicians and patients, as well as biopharmaceutical companies, in the areas of oncology. The Company is advancing its technology in the field of phosphoproteomic research. The Theralink assay uses Reverse Phase Protein Array (RPPA) technology to measure the abundance and activation of cell surface receptor proteins and their downstream signaling pathways. The Theralink platform generates an accurate and comprehensive portrait of protein pathway activation in diseased cells from each patient, and thereby determines which individuals be better responders to certain targeted molecular therapies. The platform enables the quantitative measurement of the level of activation.

View Section: Eyestock Rating